CUA Educational Content

7th Annual CUA-CUOG Multidisciplinary GU Cancers Meeting 2022


THEME OF THIS MEETING: Precision Medicine in GU Malignancies

 
Prostate Cancer
Somatic and germline genetic testing in prostate cancer | Kim Chi
Point-counter-point: Defining a role for triple therapy in metastatic castration sensitive prostate cancer | Tony Finelli & Krista Noonan
PARP-inhibitors in prostate cancer: When, who and by whom? | Kim Chi

Renal Cell Carcinoma (RCC)
Can biomarkers guide treatment decision making in RCC? | Christian Kollmannsberger
Point-counter-point: Adjuvant therapy in RCC: Ready for prime-time? | Patrick Richard & Lori Wood
Management of oligo-metastatic RCC | Jean-Baptiste Lattouf

Bladder Cancer
Evolution of multimodal therapy for non-muscle invasive bladder cancer | Girish Kulkarni
Point-counter-point: Bladder preservation after neoadjuvant chemotherapy | Fabio Cury & Ross Mason
What is optimal adjuvant therapy in bladder cancer?  | Andrea Kokorovic
Management of platinum-refractory advanced bladder cancer | Nimira Alimohamed

sponsors

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy